Diabetes mellitus predicts inferior survival in diffuse large B-cell lymphoma: a propensity score-matched analysis

References

• Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis c virus patients: a systematic review. Dig Dis Sci. 2016;61(2):636–645. doi:10.1007/s10620-015-3983-326703125
   PubMed Web of Science ®Google Scholar
• Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101. doi:10.1053/j.gastro.2007.10.04018061176
   PubMed Web of Science ®Google Scholar
• Luo W, Cao Y, Liao C, et al. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis. 2012;14(11):1307–1312. doi:10.1111/j.1463-1318.2012.02875.x23046351
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Gu C, et al. Influence of diabetes mellitus on mortality in breast cancer patients. ANZ J Surg. 2015;85(12):972–978. doi:10.1111/ans.1287725312511
   PubMed Web of Science ®Google Scholar
• Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-hodgkin’s lymphoma: a meta-analysis of observational studies. Diabetes Care. 2008;31(12):2391–2397. doi:10.2337/dc08-103419033419
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Mull N, Reagan JL, et al. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845–4850. doi:10.1182/blood-2011-06-36283022496152
   PubMed Web of Science ®Google Scholar
• Chao C, Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(5):471–480. doi:10.1093/aje/kwn16018611954
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large b-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–171. doi:10.1016/j.critrevonc.2012.12.00923375551
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes Da Silva M, Vitolo U, et al. Diffuse large b-cell lymphoma (dlbcl): esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v125. doi:10.1093/annonc/mdv30426314773
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large b-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505. doi:10.1182/asheducation-2011.1.49822160081
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Kasahara S, et al. Serum interleukin-18 level is associated with the outcome of patients with diffuse large b-cell lymphoma treated with chop or r-chop regimens. Eur J Haematol. 2011;87(3):217–227. doi:10.1111/j.1600-0609.2011.01649.x21575062
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.240317242396
   PubMed Web of Science ®Google Scholar
• National Center for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (Icd-10, Am). 3rd ed. Sydney; 2012.
   Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.3203132
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in china. N Engl J Med. 2010;362(12):1090–1101. doi:10.1056/NEJMoa090829220335585
   PubMed Web of Science ®Google Scholar
• Tseng CH. Diabetes and non-hodgkin’s lymphoma: analyses of prevalence and annual incidence in 2005 using the national health insurance database in taiwan. Ann Oncol. 2012;23(1):153–158. doi:10.1093/annonc/mdr33421765043
   PubMed Web of Science ®Google Scholar
• Yang WS, Li HL, Xu HL, et al. Type 2 diabetes and the risk of non-hodgkin’s lymphoma: a report from two population-based cohort studies in china. Eur J Cancer Prev. 2016;25(2):149–154. doi:10.1097/CEJ.000000000000015025793918
   PubMed Web of Science ®Google Scholar
• Lin SY, Hsieh MS, Chen LS, et al. Diabetes mellitus associated with the occurrence and prognosis of non-hodgkin’s lymphoma. Eur J Cancer Prev. 2007;16(5):471–478. doi:10.1097/01.cej.0000236253.93984.8f17923820
   PubMed Web of Science ®Google Scholar
• Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non-hodgkin’s lymphoma and multiple myeloma in the european prospective investigation into cancer and nutrition. Haematologica. 2008;93(6):842–850. doi:10.3324/haematol.1229718443270
   PubMed Web of Science ®Google Scholar
• Tseng CH. Diabetes, insulin use, and non-Hodgkin lymphoma mortality in taiwan. Metabolism. 2012;61(7):1003–1009. doi:10.1016/j.metabol.2011.11.01522237115
   PubMed Web of Science ®Google Scholar
• Luo J, Hendryx M, Qi L, et al. Pre-existing diabetes and lung cancer prognosis. Br J Cancer. 2016;115(1):76–79. doi:10.1038/bjc.2016.14127195423
   PubMed Web of Science ®Google Scholar
• Mu L, Zhu N, Zhang J, et al. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes Metab Res Rev. 2016;33:e2823.
   Web of Science ®Google Scholar
• Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56(11):1304–1319. doi:10.1097/DCR.0b013e3182a479f924105007
   PubMed Web of Science ®Google Scholar
• Polesel J, Gini A, Dal Maso L, et al. The impact of diabetes and other metabolic disorders on prostate cancer prognosis. J Diabetes Complications. 2016;30(4):591–596. doi:10.1016/j.jdiacomp.2016.02.00826936307
   PubMed Web of Science ®Google Scholar
• Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma–a review. Acta Oncol. 2006;45(3):258–271. doi:10.1080/0284186050053168216644568
   PubMed Web of Science ®Google Scholar
• Zhang J, Luo J, Liu F, et al. Diabetes mellitus potentiates diffuse large bcell lymphoma via high levels of ccl5. Mol Med Rep. 2014;10(3):1231–1236. doi:10.3892/mmr.2014.234124938715
   PubMed Web of Science ®Google Scholar
• Hashizume O, Shimizu A, Yokota M, et al. Specific mitochondrial DNA mutation in mice regulates diabetes and lymphoma development. Proc Natl Acad Sci U S A. 2012;109(26):10528–10533. doi:10.1073/pnas.120236710922689997
   PubMed Web of Science ®Google Scholar